Clinical Research Directory

Clinical Study of DA-002 and DA-005 as a Treatment for Hair Loss

The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).

Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

This phase III clinical trial is evaluating whether oral minoxidil 1 mg is an effective and safe treatment for women with androgenetic alopecia (female pattern hair loss). Approximately 520 women is planned to take part in the study. Participants will be randomly assigned to receive either oral minoxidil, topical minoxidil 2% solution, or placebo. Neither the participants nor the study staff will know which treatment has been assigned. The study will last up to 36 weeks, including a treatment period of 24 weeks and a follow-up period. Participants will attend regular study visits to assess hair growth and monitor safety. Site investigators will evaluate changes in hair growth and hair density using scalp imaging, investigator assessments, and participant questionnaires. Safety will be monitored through physical examinations, vital signs, laboratory tests, electrocardiograms, and the recording of side effects throughout the study.

1550nm Non-ablative Fractional Vs 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss

To evaluate the efficacy of either a 1550nm non-ablative fractional laser or a 1927nm thulium fractional laser in the treatment of female pattern hair loss (FPHL).

Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss

The goal of this clinical trial is to evaluate the efficacy and safety of OMA102 1 mg and OMA102 2 mg versus placebo in the treatment of female pattern hair loss.